Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.

Published

Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience and biobehavioral reviews
Date: 2025-06-01
Source: PubMed
DOI: 10.1016/j.neubiorev.2025.106163
PubMed: 40245969

Authors

Meshkat S Malik G Zeifman RJ Swainson J Balachandra K Reichelt AC Zhang Y Burback L Winkler O Greenshaw A Vermetten E Mayo LM Tanguay R Jetly R Bhat V

Watch author

Derived topics and classifications

psilocybin Addiction Brain Imaging Aging Microdosing Mystical Experience Clinical Trial Randomized Controlled Trial Systematic Review Review Article Observational Study Safety Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 4 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD2026-09-08 Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development2026-07-03 Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions2026-07-02 Effects of Psilocin and Psilocybin on Human 5-HT4 Serotonin and H2 Histamine Receptors in Perfused Hearts of Transgenic Mice2025-07-06

Related papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)ClinicalTrials.gov · 2024-08-15 Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03 Comparative Policy Analysis of Psychedelic Therapy Regulation in Australia, Brazil, and the USAApplied Drug Research Clinical Trials and Regulatory Affairs · 2026-09-14 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04